This laboratory study tested KP46, an orally available organic gallium complex, against four human bone-cancer cell lines and one non-malignant human fibroblast culture. KP46 killed the cancer cells at low micromolar concentrations, blocked their migration and acted together with cisplatin. The introduction summarizes how gallium compounds act in cells, mainly by competing with iron. It is pharmacology of a drug candidate, not a study of gallium in food, water or the environment.
Key numbers
- KP46 IC50 after 72 h (MTT assay), mean ± SD: MG-63 1.204 ± 0.392 µM, HOS 1.210 ± 0.344 µM, U-2 OS 3.830 ± 1.232 µM, Saos-2 1.641 ± 0.113 µM (Table 1, p. 6).
- KP46 IC50 in non-malignant human lung fibroblasts: 9.01 ± 0.012 µM; no sign of reduced fibroblast viability up to 5 µM (Table 1, p. 6; Results, p. 5).
- KP46 at 0.5 µM significantly reduced, and at 1 µM completely blocked, trans-well migration of the osteosarcoma lines tested (Results, p. 5).
- The authors state KP46 is 10 times more active than gallium chloride in vitro (Background, p. 2; secondary statement citing earlier work).
Methods (brief)
KP46 (tris(8-quinolinolato)gallium(III)) was synthesized at the University of Vienna. Cell viability was measured by MTT assay after 72 h and by clonogenic assay after 7 days; cell cycle, apoptosis, autophagy and migration were assessed with standard cell-biology assays. Results come from three independent experiments in triplicate. No gallium concentrations were measured in any biological or environmental matrix.
Evidence fitness
Useful as context on how a gallium compound behaves in human cells and on the iron-mimicry mechanism described in the introduction. It does not support dietary exposure, food or water occurrence, human toxicity thresholds or regulatory claims. Background statements on gallium salts in clinical studies and on bone affinity are secondary and cite earlier work.
Limitations
In vitro cell-line work only, with a single synthetic organic gallium complex at pharmacological concentrations. One non-malignant cell type was used as a comparison. Funding came from a City of Vienna medical research fund, and the authors declare no competing interests; one author contributed to the development of the drug.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.